Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version)-Reference-Cited by-同舟云学术

Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version)

Published:2019-07-25 Issue:9 Volume:49 Page:981-989
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Kudo Masatoshi¹^ORCID,Ikeda Masafumi²,Ueshima Kazuomi¹,Sakamoto Michiie³,Shiina Shuichiro⁴,Tateishi Ryosuke²^ORCID,Hasegawa Kiyoshi⁵,Furuse Junji⁶,Miyayama Shiro⁷^ORCID,Murakami Takamichi⁸,Yamashita Tatsuya⁹,Kokudo Norihiro¹⁰

Affiliation:

1. Department of Gastroenteology and HepatologyKindai University Faculty of Medicine Osaka Japan

2. Department of Hepatobiliary and Pancreatic OncologyNational Cancer Center Hospital East Kashiwa Japan

3. Department of PathologyKeio University School of Medicine Tokyo Japan

4. Department of GastroenterologyJuntendo University Tokyo Japan

5. Hepato‐Biliary‐Pancreatic Surgery Division, Department of SurgeryGraduate School of Medicine, University of Tokyo Tokyo Japan

6. Department of Medical OncologyKyorin University Faculty of Medicine Tokyo Japan

7. Department of Diagnostic RadiologyFukuiken Saiseikai Hospital Fukui Japan

8. Department of Diagnostic and Interventional RadiologyKobe University Graduate School of Medicine Kobe Japan

9. Advanced preventive medical sciences research centerKanazawa University Kanazawa Japan

10. National Center for Global Health and Medicine Tokyo Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13394

Reference20 articles.

1. Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version)

2. Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)

3. Pathophysiology of recurrent hepatocellular carcinoma after radiofrequency ablation

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transarterial chemoembolization refractoriness in hepatocellular carcinoma: Chinese College of Interventionalists definition and consensus statement;Chinese Medical Journal;2024-08-02

2. Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions?;Journal of Hepatocellular Carcinoma;2024-02

3. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0;Zeitschrift für Gastroenterologie;2024-02

4. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0;Zeitschrift für Gastroenterologie;2024-01

5. Impact of anticancer drugs on the therapeutic efficacy and side effects of hepatic arterial embolization for hepatocellular carcinoma;JGH Open;2023-11-10